Ekso Bionics Holdings, Inc.
EKSONASDAQHealthcare
$11.80
+$0.15(+1.29%)
Market Cap$28625502
P/E Ratio—
52W High$13.5
52W Low$2.73
Ekso Bionics Holdings, Inc. (EKSO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EKSO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
-$2.04
Est. -$0.03 · -6700.0%
Revenue
$0.00B
Est. $0.00B · -50.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
EKSO reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 27, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | Apr 28, 2026 | -$0.03 | -$2.04 | -6700.0% | $0.00B | $0.00B | -50.1% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -$0.08 | -$1.56 | -1850.0% | $0.00B | $0.01B | -37.5% |
| ▲ Q4 FY2025 | Oct 28, 2025 | -$0.99 | -$0.54 | +45.5% | $0.00B | $0.01B | -15.9% |
| ▼ Q3 FY2025 | Jul 28, 2025 | -$1.20 | -$1.24 | -3.3% | $0.00B | $0.00B | -50.4% |
| ▼ Q2 FY2025 | May 5, 2025 | -$1.65 | -$1.80 | -9.1% | $0.00B | $0.01B | -38.7% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.07 | -$0.14 | -100.0% | $0.01B | $0.00B | +6.0% |
| ▼ Q4 FY2024 | Oct 28, 2024 | -$0.08 | -$0.10 | -25.0% | $0.00B | $0.01B | -22.1% |
Q3 FY2026
Jul 27, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Miss
EPS Actual
-$2.04
EPS Est.
-$0.03
EPS Surpr.
-6700.0%
Revenue
$0.00B
Q1 FY2026
Feb 23, 2026Miss
EPS Actual
-$1.56
EPS Est.
-$0.08
EPS Surpr.
-1850.0%
Revenue
$0.00B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
-$0.54
EPS Est.
-$0.99
EPS Surpr.
+45.5%
Revenue
$0.00B
Q3 FY2025
Jul 28, 2025Miss
EPS Actual
-$1.24
EPS Est.
-$1.20
EPS Surpr.
-3.3%
Revenue
$0.00B
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$1.80
EPS Est.
-$1.65
EPS Surpr.
-9.1%
Revenue
$0.00B
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.07
EPS Surpr.
-100.0%
Revenue
$0.01B
Q4 FY2024
Oct 28, 2024Miss
EPS Actual
-$0.10
EPS Est.
-$0.08
EPS Surpr.
-25.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q1 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2025 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2025 | $-0.96 | $-0.96 | $-0.96 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 28, 2026 | -6700.0% | $11.37 | $11.21 | -1.41% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -1850.0% | $11.18 | $10.64 | -4.83% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +45.5% | $4.92 | $4.81 | -2.24% |
| ▼ Q3 FY2025 | Jul 28, 2025 | -3.3% | $4.82 | $4.53 | -6.02% |
| ▼ Q2 FY2025 | May 5, 2025 | -9.1% | $7.25 | $7.15 | -1.38% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -100.0% | $7.87 | $7.23 | -8.13% |
| ▼ Q4 FY2024 | Oct 28, 2024 | -25.0% | $15.60 | $16.95 | +8.65% |
| ▼ Q3 FY2024 | Jul 29, 2024 | -18.2% | $19.50 | $22.35 | +14.62% |
Q2 FY2026-1.41%
Report Date
Apr 28, 2026
EPS Beat/Miss
-6700.0%
Price Before
$11.37
Price After
$11.21
Q1 FY2026-4.83%
Report Date
Feb 23, 2026
EPS Beat/Miss
-1850.0%
Price Before
$11.18
Price After
$10.64
Q4 FY2025-2.24%
Report Date
Oct 28, 2025
EPS Beat/Miss
+45.5%
Price Before
$4.92
Price After
$4.81
Q3 FY2025-6.02%
Report Date
Jul 28, 2025
EPS Beat/Miss
-3.3%
Price Before
$4.82
Price After
$4.53
Q2 FY2025-1.38%
Report Date
May 5, 2025
EPS Beat/Miss
-9.1%
Price Before
$7.25
Price After
$7.15
Q1 FY2025-8.13%
Report Date
Mar 3, 2025
EPS Beat/Miss
-100.0%
Price Before
$7.87
Price After
$7.23
Q4 FY2024+8.65%
Report Date
Oct 28, 2024
EPS Beat/Miss
-25.0%
Price Before
$15.60
Price After
$16.95
Q3 FY2024+14.62%
Report Date
Jul 29, 2024
EPS Beat/Miss
-18.2%
Price Before
$19.50
Price After
$22.35
Avg Beat Reaction-2.24%
Avg Miss Reaction+0.21%
Beat Rate1 / 8 quarters
Largest Move+14.62% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EKSO ends December
Ekso Bionics Holdings, Inc. (EKSO) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $-2.04 — missing the analyst consensus of $-0.03 by -6700.0%. The next EKSO earnings date is expected around September 1, 2026.
Each quarter, investors track EKSO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EKSO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EKSO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EKSO earnings · 5 questionsEkso Bionics Holdings, Inc.'s next earnings report is expected around September 1, 2026. EKSO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EKSO historically reports after market close (AMC).
EKSO earnings datewhen is EKSO earningsEKSO next earnings datewhen does EKSO report earningsEKSO earnings calendar
▸ Source: FMP · Ekso Bionics Holdings, Inc. SEC filings · US GAAP · Ekso Bionics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026